DNDmitrii S. Novginov

Dmitrii S. Novginov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dmitrii S. Novginov has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Glycemia monitoring in the prevention of complications of pregnancy in type 1 diabetes mellitus

    by N.M. Startseva, M.I. Sviridova, Sh.S.A. Imrayzeeq, D.S. Novginov, N.P. Romm, A.S. Anikeev, A.A. Artamonova

  • Cesarean scar pregnancy: problem-solving methodologies and approaches

    by A.I.D Avydov, M.B.K Hamoshina, R.A.C Hilova, D.S.N Ovginov, A.A.G Asratova, D.G.A Vetisyan

    This article discusses the epidemiology, classification, diagnosis, and treatment of cesarean scar pregnancy (CSP). The main ultrasound signs of CSP and their significance in choosing a treatment strategy are presented, which depends on many clinical and anamnestic factors, namely: the type of CSP, gestational age, residual myometrial thickness, and the degree of ectopic trophoblast invasion into the surrounding tissues. A number of aspects related to hemostasis in CSP are critically analyzed. In particular, it is shown that transvaginal ligation of the descending branch of uterine artery is more effective in terms of hemostasis compared to uterine artery embolization in CSP with mild invasion of chorionic villi into the myometrium. The role of operative hysteroscopy in the treatment of patients with CSP is analyzed in detail. The material is supplemented with a clinical case report. Key words: cesarean scar pregnancy, epidemiology, classification, diagnosis, treatment, uterine artery embolization, operative hysteroscopy

  • Open Access

    Clinical and anamnestic characteristics of obese pregnant women

    by K.A. Gulenkova, A.A. Orazmuradov, D.S. Novginov, M.T. Khubetsova, T.N. Zulumyan, E.V. Loginova

    Клинико-анамнестическая характеристика беременных с ожирением

  • Open Access

    Molecular genetic and biochemical markers of preeclampsia in obese women

    by I.V. Bekbaeva, A.A. Orazmuradov, K.A. Gulenkova, I.N. Kostin, D.S. Novginov, M.T. Khubetsova

    Молекулярно-генетические и биохимические маркеры преэклампсии у женщин с ожирением

  • Open Access

    Morphological features of early reproductive losses in obesity

    by E.A. Kuzmina, A.A. Orazmuradov, L.E. Gaganov, D.S. Novginov, O.K. Doronina, M.S. Dikkaya

    Морфологические особенности ранних репродуктивных потерь при ожирении

  • Open Access

    Prediction of full-term antenatal fetal death

    by E.V. Mukovnikova, A.A. Orazmuradov, I.N. Kostin, D.S. Novginov, T.N. Zulumyan, G.A. Orazmuradova

    Прогнозирование антенатальной гибели плода в доношенном сроке

  • Open Access

    Endometriosis: progestogen therapy. What’s new?

    by M.B. Khamoshina, D.S. Novginov, M.S. Tulupova, Yu.S. Artemenko, V.A. Ryabova

    Эндометриоз: терапия прогестагенами. Что нового?

  • Open Access

    Non-invasive diagnostics of endometriosis based on plasma miRNA expression

    by I. M. Ordiyants, D. S. Novginov, Z. V. Zyukina, A. M. Khachatryan, S. E. Titov

    Aim. To develop a method for noninvasive diagnosis of external genital endometriosis based on plasma microRNA concentrations.Materials and Methods. 80 women of reproductive age who were admitted to the gynecological department for routine laparoscopy were retrospectively examined, according to the results of which and histological examination, the patients were divided into 2 groups: the main group — 54 patients with laparoscopically and histologically confirmed external genital endometriosis (EGE); the control group — 26 patients without EGE. Before laparoscopy, a blood sample was taken from all patients for a molecular-biological study of the expression of 10 microRNAs: miR-183, miR-125b, miR-126, miR-16, miR-15a, miR-200a, miR-20a, miR-21, miR-222 and miR-29b. Identification of the studied and normalizing RNAs (U6 RNA and 103a microRNA) was performed according to the method of Chen et al. The presented values of the expression of the studied microRNAs are given in the form of 2-ΔCt. The expression ratio is given in the form of 2-ΔCt (main)/2-ΔCt (control), if the expression in the group of patients with endometriosis exceeded that in the control group, and in the form of 2-ΔCt (control)/2-ΔCt (main), if vice versa.Results. Comparison of the expression of 10 mi-croRNAs between the two groups revealed statistically significant differences only in miR-183: its expression in patients with EGE was statistically 1.5 times higher than that in women of the control group (p=0.017).We have not detected a difference in the expression of mir-200a, while according to other researchers, representatives of the mir-200 family are among the most frequent whose expression changes with endometriosis. MIR-16 expression also did not differ statistically among the patients we examined, whereas a group of American colleagues revealed its increase in patients with endometriosis and with endometriosis-associated ovarian tumors. We found no difference in mir-21 expression. The results of other researchers are contradictory: some found its increase in endometrioid cysts compared with eutopic endometrium, an increase in the epithelium of the fallopian tubes with their endometriosis compared with unaffected; others did not reveal a difference between the eutopic endometrium of endometriosis patients and healthy women, but showed a decrease in expression in peritoneal foci and foci of deep infiltrative endometriosis compared with eutopic endometrium.The expression of mir-222 was reduced in the patients we examined with endometriosis, which goes against the existing ideas about the pro-oncogenic role of this microRNA. An increase in its expression in cancer of the stomach, bladder, liver, lungs, breast, endometrium, ovaries is described. At the same time, the oncosuppressive effect of mir-222 is also known in prostate cancer, squamous cell carcinoma of the oral cavity.Conclusion. Taking into account the revealed statistically significant difference in microRNA expression by ROC analysis, we determined their effectiveness and specificity in the diagnosis of EGE. Of course, further studies with a large contingent of patients are needed to confirm the diagnostic value of these biomarkers. In addition, our study did not allow us to establish a statistical difference in microRNA expression in patients with impaired fertility. But it is the test that makes it possible to differentiate female infertility — associated with endometriosis and without it, as a rule, tubal-peritoneal genesis — that will become a key tool in the personalized management of patients with infertility.In our work, the distribution of patients by stages of EGE turned out to be uneven (there were no women with stage I at all) and it was not possible to establish a statistical difference in microRNA expression depending on the "length of service" of the disease.


  • Open Access

    Neuroprotective effects of estetrol in combined oral contraceptives: A review

    by Mekan R. Orazov, Vasily V. Ermakov, Dmitrii S. Novginov

    One of the most effective contraception methods is combined hormonal contraceptives. According to the current prescribing information, in addition to their primary effect, they have several concomitant positive effects on the female body non-contraceptive effects. These include a well-predictable and controlled "menstrual cycle" (menstrual-like reaction), anti-androgenic effect, anti-anemic effect due to reduced menstrual blood loss, reducing the severity of dysmenorrhea and premenstrual syndrome, reducing the risk of pelvic inflammatory diseases, ectopic pregnancy, and some benign and malignant tumors of the reproductive system. Combined oral contraceptives (COCs) also have effects on the central nervous system, hypothalamic-pituitary structures that regulate sex hormones, and the psycho-emotional health of women. For a long time, the main estrogen component of COCs remained ethinylestradiol. Although not well-studied, its mechanisms of action on the nervous system are similar, regardless of the progestogen component. However, the effect was not entirely positive: taking contraceptives containing ethinylestradiol can lead to increased emotional lability, anxiety, and depressive disorders. It drives researchers to search for new estrogen without these adverse properties. Such is the long-known but overlooked esthetrol. Numerous studies indicate a pronounced neuroprotective effect of esthetrol, which can increase patients' satisfaction with hormonal contraceptives and their compliance. It also opens up great opportunities for the use of this drug beyond gynecological practice.